How were Cerecor's earnings last quarter?

Cerecor Inc. (NASDAQ:CERC) announced its quarterly earnings results on Sunday, August, 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business earned $3.36 million during the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%.

What other stocks do shareholders of Cerecor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Bionano Genomics (BNGO) , Gran Tierra Energy (GTE) , KushCo (KSHB) , Novan (NOVN) , Zosano Pharma (ZSAN) , Aeterna Zentaris (AEZS) , Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI) .

NASDAQ:CERC

Cerecor (CERC) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free CERC Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $11.50
▼
$13.02
50-Day Range: $2.06
▼
$3.24
52-Week Range: $1.98
▼
$4.50

Volume: 68,159 shs
Average Volume: 1.27 million shs
Market Capitalization: $1.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Insider Trades Social Media

Get Cerecor alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Cerecor Stock (NASDAQ:CERC)

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

CERC Stock News Headlines

December 19, 2023 | benzinga.com

Aytu BioPharma Stock (NASDAQ:AYTU) Insider Trades

August 24, 2023 | uk.finance.yahoo.com

mTOR Inhibitors Global Market Report 2023

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

May 11, 2023 | finance.yahoo.com

DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape

September 28, 2022 | finance.yahoo.com

Edited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT - Yahoo Finance

September 28, 2022 | seekingalpha.com

Aytu BioPharma, Inc. (AYTU) CEO Josh Disbrow on Q4 2022 Results - Earnings Call Transcript - Seeking Alpha

August 31, 2022 | marketwatch.com

DiGeorge Syndrome Drug Market In-Depth Analysis Research Report 2029

August 24, 2022 | streetinsider.com

ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - StreetInsider.com

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

August 24, 2022 | businesswire.com

ValenzaBio Appoints Industry Veteran Peter Greenleaf to its Board of Directors - Business Wire

August 11, 2022 | globenewswire.com

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire

August 9, 2022 | streetinsider.com

Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update - StreetInsider.com

August 8, 2022 | marketscreener.com

Celldex Therapeutics : Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Form 8-K - Marketscreener.com

July 24, 2022 | seekingalpha.com

Avalo Therapeutics, Inc. (AVTX) Stock Price Today, Quote & News - Seeking Alpha

July 15, 2022 | bizjournals.com

Philadelphia biotech news: Updates from CHOP, Helius Medical, GSK and more - Philadelphia Business Journal - The Business Journals

May 3, 2022 | prnewswire.com

The Axial Spondyloarthritis Market is Predicted to Grow with a CAGR of 4.7% by 2032, Analyzes DelveInsight - PR Newswire

May 1, 2022 | marketwatch.com

DiGeorge Syndrome Drug Market Size, Share, Industry Growth & Forecast By 2029

April 8, 2022 | marketscreener.com

AACR Poster Presentation: CFT7455 Phase 1/2 Cohort A - Marketscreener.com

March 28, 2022 | benzinga.com

DiGeorge Syndrome Drug Market High Demand, Size, Share, Processing Industry, And Forecast By 2029 - Benzi - Benzinga

November 10, 2021 | businesswire.com

Model N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Business Wire

November 10, 2021 | nasdaq.com

Model N (MODN) Q4 Earnings & Revenues Top Estimates, Up Y/Y - Nasdaq

November 9, 2021 | finance.yahoo.com

Model N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Yahoo Finance

November 9, 2021 | finance.yahoo.com

Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates - Yahoo Finance

November 9, 2021 | stockhouse.com

Model N Announces Fourth Quarter and Fiscal Year 2021 Financial Results - Stockhouse

October 7, 2021 | finance.yahoo.com

Horizon Technology Finance Provides Third Quarter 2021 Portfolio Update - Yahoo Finance

August 27, 2021 | bizjournals.com

Inovio's experimental Covid-19 vaccine takes another step, plus other life sciences news - Philadelphia Business Journal - Philadelphia Business Journal

August 27, 2021 | marketscreener.com

CERECOR : Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc (Form 8-K) - Marketscreener.com

See More Headlines

Receive CERC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerecor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/01/2021
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CERC
CUSIP: N/A
CIK: 1534120
Web: www.cerecor.com
Phone: (410) 522-8707
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,500,000.00
Net Margins: -1,194.82%
Pretax Margin: N/A
Return on Equity: -261.82%
Return on Assets: -133.96%

Debt

Debt-to-Equity Ratio: 0.79
Current Ratio: 2.19
Quick Ratio: 2.18

Sales & Book Value

Annual Sales: $6.70 million
Price / Sales: 172.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.22 per share
Price / Book: 54.59

Miscellaneous

Outstanding Shares: 96,009,000
Free Float: N/A
Market Cap: $1.15 billion
Optionable: Not Optionable
Beta: 1.44

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Michael F. Cola
Chairman & Chief Executive Officer
Schond L. Greenway
Chief Financial Officer & Treasurer
H. Jeffrey Wilkins
Chief Medical Officer
Garry Arthur Neil
Chief Scientific Officer
Younok Dumortier Shin
Chief Technology Officer

Key Competitors

View All Competitors

CERC Stock Analysis - Frequently Asked Questions

How were Cerecor's earnings last quarter?: Cerecor Inc. (NASDAQ:CERC) announced its quarterly earnings results on Sunday, August, 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business earned $3.36 million during the quarter. Cerecor had a negative net margin of 1,194.82% and a negative trailing twelve-month return on equity of 261.82%.
What other stocks do shareholders of Cerecor own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerecor investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), KushCo (KSHB), Novan (NOVN), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

This page (NASDAQ:CERC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cerecor (CERC) Stock Price, News & Analysis

About Cerecor Stock (NASDAQ:CERC)

CERC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CERC Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info